Published in J Clin Oncol on June 29, 2009
ReCAP: Serum Tumor Marker Use in Patients With Advanced Solid Tumors. J Oncol Pract (2015) 2.01
Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer (2013) 1.21
Low-volume plus ascorbic acid vs high-volume plus simethicone bowel preparation before colonoscopy. World J Gastroenterol (2011) 1.06
Physician follow-up and observation of guidelines in the post treatment surveillance of colorectal cancer. Surgery (2013) 0.88
CT colonography in the diagnosis and management of colorectal cancer: emphasis on pre- and post-surgical evaluation. World J Gastroenterol (2014) 0.87
Patterns and treatment of recurrence following pulmonary resection for colorectal metastases. World J Surg (2015) 0.80
Caution is required before recommending routine carcinoembryonic antigen and imaging follow-up for patients with early-stage colon cancer. J Clin Oncol (2009) 0.80
Postoperative serum levels of sCD26 for surveillance in colorectal cancer patients. PLoS One (2014) 0.79
Six-year experience of a nurse-led colorectal cancer follow-up clinic. Surg Res Pract (2014) 0.77
Surveillance for early stages of colon cancer: potentials for optimizing follow-up protocols. World J Surg Oncol (2015) 0.76
Evidence-based treatment of patients with rectal cancer. Oncol Lett (2016) 0.75
Inferior vena cava enteric fistula due to unresected colorectal metastasis. World J Emerg Surg (2015) 0.75
Post-Resection Surveillance in GI Cancers. Indian J Surg (2013) 0.75
Is limited surgery justified in the treatment of T1 colorectal cancer? Surg Endosc (2012) 0.75
Trends in surveillance for resected colorectal cancer, 2001-2009. Cancer (2015) 0.75
Hypermethylated DNA, a circulating biomarker for colorectal cancer detection. PLoS One (2017) 0.75
Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg (1999) 14.31
Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg (2004) 6.75
Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg (2008) 4.86
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol (2003) 4.34
Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol (2005) 4.10
Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg (2004) 2.65
Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol (2005) 2.48
Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev (2007) 2.27
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol (2007) 2.10
Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol (1992) 1.91
Pulmonary resection for metastases from colorectal cancer: factors influencing prognosis. Twenty-year experience. Eur J Cardiothorac Surg (2002) 1.79
Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur J Surg Oncol (2002) 1.55
Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg (1998) 1.54
Practice parameters for the surveillance and follow-up of patients with colon and rectal cancer. Dis Colon Rectum (2004) 1.26
Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114. J Clin Oncol (2003) 1.06
Imaging techniques contribute to increased surgical rescue of relapse in the follow-up of colorectal cancer. Dis Colon Rectum (2006) 0.90
A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med (2004) 19.45
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol (2003) 12.24
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med (2003) 12.17
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet (2012) 12.00
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol (2004) 7.36
Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. JAMA (2002) 6.21
Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol (2002) 5.91
The genome of woodland strawberry (Fragaria vesca). Nat Genet (2010) 5.86
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol (2009) 5.42
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial. Ann Surg (2007) 5.30
Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol (2007) 4.60
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol (2011) 4.56
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol (2006) 4.27
Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol (2009) 4.09
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst (2011) 4.08
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol (2005) 3.88
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol (2006) 3.70
Meta-analysis for surrogacy: accelerated failure time models and semicompeting risks modeling. Biometrics (2011) 3.38
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA (2013) 3.38
Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol (2009) 3.08
Transanal minimally invasive surgery: a giant leap forward. Surg Endosc (2010) 2.93
Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA (2007) 2.84
Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol (2008) 2.74
Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med (2008) 2.74
Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol (2008) 2.58
Laparoscopically assisted vs open colectomy for colon cancer: a meta-analysis. Arch Surg (2007) 2.52
Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes. J Clin Oncol (2009) 2.47
Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol (2002) 2.33
Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation. J Clin Oncol (2009) 2.32
Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res (2008) 2.32
Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol (2004) 2.30
Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials. J Clin Oncol (2005) 2.28
Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clin Trials (2010) 2.24
Surgeon volume does not predict outcomes in the setting of technical credentialing: results from a randomized trial in colon cancer. Ann Surg (2008) 2.19
Obesity is an independent prognostic variable in colon cancer survivors. Clin Cancer Res (2010) 2.18
An adaptive dose-finding design incorporating both toxicity and efficacy. Stat Med (2006) 2.16
A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery (2005) 2.10
National Institutes of Health state-of-the-science conference statement: prevention of fecal and urinary incontinence in adults. Ann Intern Med (2008) 2.10
Use and outcomes of laparoscopic-assisted colectomy for cancer in the United States. Arch Surg (2008) 2.10
Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology (2009) 2.04
Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology (2006) 2.02
Stereotactic navigation for TAMIS-TME: opening the gateway to frameless, image-guided abdominal and pelvic surgery. Surg Endosc (2014) 1.89
A novel risk-adjusted nomogram for rectal cancer surgery outcomes. JAMA Surg (2013) 1.88
Biomarkers and surrogate end points--the challenge of statistical validation. Nat Rev Clin Oncol (2010) 1.87
Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol (2011) 1.84
Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. J Clin Oncol (2008) 1.82
Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res (2008) 1.76
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol (2008) 1.74
USPSTF recommendations for STI screening. Am Fam Physician (2008) 1.68
Loop ileostomy reversal after colon and rectal surgery: a single institutional 5-year experience in 944 patients. Arch Surg (2011) 1.66
Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma. J Clin Oncol (2002) 1.65
Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741. J Clin Oncol (2011) 1.64
Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol (2013) 1.62
Is the increasing rate of local excision for stage I rectal cancer in the United States justified?: a nationwide cohort study from the National Cancer Database. Ann Surg (2007) 1.62
Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. J Clin Oncol (2004) 1.61
Saturated linkage map construction in Rubus idaeus using genotyping by sequencing and genome-independent imputation. BMC Genomics (2013) 1.61
Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol (2010) 1.61
Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res (2012) 1.57
Optimising the design of phase II oncology trials: the importance of randomisation. Eur J Cancer (2008) 1.54
Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials. Biometrics (2011) 1.54
Designing a randomized clinical trial to evaluate personalized medicine: a new approach based on risk prediction. J Natl Cancer Inst (2010) 1.53
Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials. J Clin Oncol (2009) 1.53
An interactive individualized intervention to promote behavioral change to increase personal well-being in US surgeons. Ann Surg (2014) 1.52
Stapled transanal rectal resection vs. transvaginal rectocele repair for treatment of obstructive defecation syndrome. Dis Colon Rectum (2009) 1.52
Alternate endpoints for screening phase II studies. Clin Cancer Res (2009) 1.47
Substitution of oral fluoropyrimidines for infusional fluorouracil with radiotherapy: how much data do we need? J Clin Oncol (2004) 1.46
Postoperative morbidity with diversion after low anterior resection in the era of neoadjuvant therapy: a single institution experience. J Am Coll Surg (2009) 1.44
Clinical trial designs for prospective validation of biomarkers. Am J Pharmacogenomics (2005) 1.43
Development of a dense SNP-based linkage map of an apple rootstock progeny using the Malus Infinium whole genome genotyping array. BMC Genomics (2012) 1.42
Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups. Clin Cancer Res (2011) 1.42
Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol (2013) 1.41
Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol (2004) 1.41
Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. J Clin Oncol (2010) 1.40
Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst (2012) 1.39
Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers. Am J Gastroenterol (2006) 1.34
An evaluation of the PacBio RS platform for sequencing and de novo assembly of a chloroplast genome. BMC Genomics (2013) 1.33
Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol (2009) 1.32
Assessing the measure of a new drug: is survival the only thing that matters? J Clin Oncol (2008) 1.30
Clinical trial designs for predictive biomarker validation: one size does not fit all. J Biopharm Stat (2009) 1.30
Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas. PLoS One (2012) 1.30
Synteny conservation between two distantly-related Rosaceae genomes: Prunus (the stone fruits) and Fragaria (the strawberry). BMC Plant Biol (2008) 1.29
An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations. Stat Med (2007) 1.29
Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation. J Clin Oncol (2010) 1.28
Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. Int J Radiat Oncol Biol Phys (2002) 1.27
Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer (2013) 1.25
Predictive biomarker validation in practice: lessons from real trials. Clin Trials (2010) 1.24
Integrating biomarkers in clinical trials. Expert Rev Mol Diagn (2011) 1.24
Drug rechallenge and treatment beyond progression--implications for drug resistance. Nat Rev Clin Oncol (2013) 1.22